Research programme: neuroprotectants - Trophos
Alternative Names: Cholesterol-oxime compounds - Roche; TRO-11592; TRO-17416; TRO-20021; TRO-51644; TRO-6391Latest Information Update: 04 Nov 2017
At a glance
- Originator Trophos
- Developer Roche
- Class Cholestenones; Oximes; Small molecules
- Mechanism of Action Mitochondrial permeability transition pore modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Huntington's disease; Multiple sclerosis; Neurological disorders; Neuropathic pain; Pain; Parkinson's disease; Reperfusion injury; Spinal muscular atrophy
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in European Union
- 04 Nov 2017 No recent reports of development identified for preclinical development in Huntington's-disease in European Union
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in European Union